Foundation Medicine, Inc.
NEWS
The first project the companies aim to develop is a companion diagnostic for Vitrakvi, the only TRK inhibitor approved in the U.S. for patients with TRK fusion cancer across all solid tumors.
For its 2019 list of the top 50 most innovative companies, Fast Company selected 10 from the biotech industry that are having a significant impact on the treatment of patients. The first five are highlighted.
On August 29, Chicago-based Tempus, which focuses on data analytics for molecular and clinical data, announced it had raised $110 million in Series E financing. This brought total money raised so far to $320 million. This also gave the company a valuation of $2 billion.
Only a matter of days after Roche filed its second-quarter financial report, it’s had plenty of news to report.
Investors love their takeover rumors, and with biopharma having a good year for mergers and acquisitions, there’s been plenty to keep them busy. Here’s two takeover rumors that came out of Spanish media group Intereconomia.
Both “rare cancers” and “sub-populations of cancers” present a challenge to companies conducting clinical trials—finding enough patients for those trials.
Three years after acquiring a majority stake Foundation Medicine, Pharma giant Roche has agreed to buy up all outstanding shares for about $2.4 billion and bring the company’s sequencing diagnostics platform under the Roche umbrella.
The following is a roundup of presentations and findings from multiple companies participating in the 2018 American Association for Cancer Research (AACR) in Chicago.
A look at the latest batch of FDA approvals this year.
JOBS
IN THE PRESS